Quick Read – JNJ has surged 55% over the past year to $232.77, but hitting $300 by year-end demands a 29% gain and a 26x forward P/E. – Oncology drugs TREMFYA and RYBREVANT/LAZCLUZE surged over 68% in Q1, while talc litigation and STELARA biosimilar erosion drove net income down…
%. – Wall Street targets $253 for JNJ, but a DCF model places intrinsic value at $374, suggesting consensus is underpricing the pipeline. – Johnson & Johnson (NYSE:JNJ) has rallied 13.73% year to date and 55.27% over the past year, fueled by oncology blockbusters and a MedTech franchise hitting on every cylinder. CEO Joaquin Duato told investors that “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact.” The stock sits at $232.77
Can it push to $300 before year-end? What’s Holding JNJ Back Right Now Despite strong gains, JNJ has cooled. Shares are up just 3.3% over the past week and 4.23% over the past month after a May pullback.
Q1 2026 net income fell 52.4% YoY, hammered by $330 million in litigation charges and 59.7% STELARA biosimilar erosion. An FDA Early Alert on Abiomed catheter kits and ongoing talc litigation testimony create overhang. With a beta of just 0.256, JNJ rarely moves fast, so reaching $300 requires a clear catalyst to re-rate the multiple higher.